Screener
Theravance Biopharma TBPH Transaction Related Expenses Acquiree
Transaction Related Expenses Acquiree at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept tbph:TransactionRelatedExpensesAcquiree.
The source filing: Theravance Biopharma’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 8:00 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-093773
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Research and development (1) | 4,712 | 10,490 | 10,541 | 21,942 |
| Selling, general and administrative (1) | 14,176 | 18,430 | 31,896 | 36,800 |
| Restructuring expenses (1) (2) | 4,031 | — | 7,664 | — |
| Transaction-related expenses | 6,089 | — | 6,089 | — |
| Total expenses | 29,008 | 28,920 | 56,190 | 58,742 |
| Loss from operations | (8,277) | (2,725) | (17,760) | (17,159) |
| Net gain on realized contingent milestone and royalty assets | — | 75,137 | — | 75,137 |
| Interest expense (non-cash) | — | (663) | — | (1,306) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Theravance Biopharma's transaction related expenses acquiree?
- Theravance Biopharma (TBPH) reported transaction related expenses acquiree of $6.09M in Q2 2026.
- What does transaction related expenses acquiree mean?
- Transaction Related Expenses Acquiree as reported by Theravance Biopharma, Inc..
Ask your AI about Theravance Biopharma's transaction related expenses acquiree.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude